Changzhou Qianhong BiopharmaLTD (002550) Stock Overview
Manufactures and distributes polysaccharide and protease drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
002550 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Changzhou Qianhong Biopharma CO.,LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.22 |
| 52 Week High | CN¥9.38 |
| 52 Week Low | CN¥4.87 |
| Beta | 0.26 |
| 1 Month Change | 35.20% |
| 3 Month Change | 47.31% |
| 1 Year Change | 48.38% |
| 3 Year Change | 51.10% |
| 5 Year Change | 94.79% |
| Change since IPO | 67.67% |
Recent News & Updates
Recent updates
Do Changzhou Qianhong BiopharmaLTD's (SZSE:002550) Earnings Warrant Your Attention?
Nov 18
Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) Held Back By Insufficient Growth Even After Shares Climb 37%
Oct 21Here's Why Changzhou Qianhong BiopharmaLTD (SZSE:002550) Can Manage Its Debt Responsibly
Aug 21Changzhou Qianhong BiopharmaLTD (SZSE:002550) Has Affirmed Its Dividend Of CN¥0.12
May 26Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) Looks Just Right With A 26% Price Jump
May 21Investors Can Find Comfort In Changzhou Qianhong BiopharmaLTD's (SZSE:002550) Earnings Quality
May 02Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?
Mar 24Shareholder Returns
| 002550 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 14.5% | 5.6% | 1.5% |
| 1Y | 48.4% | 13.4% | 12.6% |
Return vs Industry: 002550 exceeded the CN Pharmaceuticals industry which returned 13.4% over the past year.
Return vs Market: 002550 exceeded the CN Market which returned 12.6% over the past year.
Price Volatility
| 002550 volatility | |
|---|---|
| 002550 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 9.9% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 002550 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002550's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 979 | Ke Wang | www.qhsh.com.cn |
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers its products in the form of tablets, hard capsules, lyophilized powder and lyophilized powder injections, small-volume injections, and raw materials. It provides enzymes, including pancreatic kininogenase series, asparaginase series, and compound digestive enzyme capsule II; and polysaccharides products, such as nadroparin calcium, enoxaparin sodium, dalteparin sodium, and asparaginase and heparin sodium.
Changzhou Qianhong Biopharma CO.,LTD Fundamentals Summary
| 002550 fundamental statistics | |
|---|---|
| Market cap | CN¥11.26b |
| Earnings (TTM) | CN¥412.89m |
| Revenue (TTM) | CN¥1.52b |
Is 002550 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002550 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.52b |
| Cost of Revenue | CN¥685.86m |
| Gross Profit | CN¥830.16m |
| Other Expenses | CN¥417.27m |
| Earnings | CN¥412.89m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.33 |
| Gross Margin | 54.76% |
| Net Profit Margin | 27.24% |
| Debt/Equity Ratio | 0.7% |
How did 002550 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/05 14:16 |
| End of Day Share Price | 2025/06/05 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Changzhou Qianhong Biopharma CO.,LTD is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peng Yan | Changjiang Securities Co. LTD. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Mingrui Wang | Everbright Securities Co. Ltd. |